Truist Securities Reiterates Buy on Biogen, Raises Price Target to $260
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsReiterationPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Truist Securities analyst Danielle Brill reiterates Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $235 to $260.
Truist Securities analyst Danielle Brill reiterates Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $235 to $260.
More on BIIB
Benzinga
Eisai And Biogen Present Findings From Analysis Of Lecanemab-Irmb Treatment And α-Syn Co-Pathology In Cerebrospinal Fluid Substudy Of Clarity AD In Early Alzheimer’s Disease, At CTAD ConferenceLecanemab showed favorable results on clinical assessment scores at 18 months, including among individuals with early Alzheimer’s disease (AD) who were α-synuclein positive, a subgroup associated…
